help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobin, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobin, M. J.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 277-287, (2004)
© 2004 American Thoracic Society


Year in Review

Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2003

Martin J. Tobin

Division of Pulmonary and Critical Care Medicine, Loyola University of Chicago Stritch School of Medicine and Hines Veterans Affairs Hospital, Hines, Illinois

Correspondence and requests for reprints should be addressed to Martin J. Tobin, M.D., Division of Pulmonary and Critical Care Medicine, Hines Veterans Affairs Hospital, Route 111N, Hines, IL 60141. E-mail: mtobin2{at}lumc.edu


    CONTENTS
 TOP
 CONTENTS
 PEDIATRICS
 SURFACTANT BIOLOGY AND DISORDERS
 CYSTIC FIBROSIS
 REFERENCES
 
Pediatrics (46)

  Pulmonary Function Testing and Diagnostic Techniques (4)

    Normative Values (2)

    Thoracoabdominal Compression (1)

    Respiratory Muscles and Mechanics (1)

  Mechanical Ventilation (3)

  Respiratory Syncytial Virus Bronchiolitis (4)

  Sleep and Control of Breathing (7)

  Pediatric Asthma (11)

    Epidemiology (3)

    Airway Inflammation (6)

    Treatment (2)

  Other Pediatric Issues (17)

    Air Pollution (2)

    In utero Exposure to Cigarette Smoke (4)

    Maternal Asthma (1)

    Lung Development (2)

    Bronchopulmonary Dysplasia (7)

    Infections and Sepsis (1)

Surfactant Biology and Disorders (8)

  Pathophysiology (3)

  Deficiency (2)

  Treatment (3)

Cystic Fibrosis (25)

  Genetics (3)

  Lung Inflammation (2)

  Microbiology (3)

  Pathophysiology and Exercise Performance (8)

  Treatment (9)

    Gene Therapy (2)

    Mucolytic Agents (1)

    Antibiotic Therapy (5)

    Outcome (1)


    PEDIATRICS
 TOP
 CONTENTS
 PEDIATRICS
 SURFACTANT BIOLOGY AND DISORDERS
 CYSTIC FIBROSIS
 REFERENCES
 
Pulmonary Function Testing and Diagnostic Techniques
Normative values.
Pulmonary function in children is commonly normalized for subject height, but height is an unreliable reference standard in children with neuromuscular weakness or spinal deformity. In 1,444 boys and 1,999 girls (ages 5.3 to 19.6 years), Gauld and coworkers (1) investigated the relationship between pulmonary function and limb length. Prediction equations that included both ulnar length and age were predictive of forced expiratory volume in one second (FEV1) (r2 = 0.86 for boys and 0.84 for girls) and forced vital capacity (FVC) (r2 = 0.86 for boys and 0.83 for girls). Precision was equivalent to that provided by height. The authors conclude that pulmonary function can be reliably predicted on the basis of ulnar length in children whose height is difficult to measure.

Reported values for functional residual capacity (FRC) in infants have declined, for unexplained reasons, over the last 30 years. Hulskamp and coworkers (2) measured lung volume with a new plethysmograph in 32 healthy infants. Mean FRC was 19.6 ml per kg. Compared with recently collated data from the a task force of the American Thoracic Society, mean FRC was 7.0 ml per kg lower. A total of 66% of healthy infants had values for FRC below the normal range. The authors conclude that new reference standards for lung function in infants need to be established.

Thoracoabdominal compression.
To determine the ability of forced expiratory flow–volume curves (obtained by the raised volume rapid compression technique) to discriminate between groups of infants with differing severities of respiratory symptoms, Jones and coworkers (3) studied 33 infants (aged 36 weeks) with previous respiratory symptoms but currently asymptomatic and 36 infants (aged 58 weeks) with respiratory symptoms at the time of evaluation. All variables derived from flow-volume curves, with the exception of FVC, distinguished between the symptomatic and asymptomatic infants. The mean Z scores for volume-referenced forced expiratory flows (FEF50, FEF75, and FEF25–75) were more negative than the Z scores for the timed expired volumes (FEV0.5 and FEV0.5/FVC) for both groups. The forced expiratory flow at 50% of forced vital capacity (FEF50) had the highest performance in detecting abnormal lung function. The authors conclude that flow-volume curves obtained by the raised volume rapid compression technique can discriminate between groups of infants with respiratory symptoms of differing severity and that measures of forced expiratory flows are superior to timed expiratory volumes in detecting abnormal airway function.

Respiratory muscles and mechanics.
Beydon and coworkers (4) compared pulmonary function in 74 preschool children with asthma and 84 healthy control subjects. The children with asthma had a 19% higher expiratory resistance than did the control children. Children with asthma who developed symptoms on exercise had higher resistance than did children without symptoms on exercise. A bronchodilator achieved a greater decrease in resistance in children with asthma than in control subjects (18.6% versus 11.2% decrease in baseline resistance). A decrease in resistance of 35% after bronchodilator was 3 times more likely in children with asthma than in healthy children. The authors conclude that measurement of pulmonary function is helpful in discriminating between preschool children with and without asthma.

Mechanical Ventilation
To design clinical trials in mechanically ventilated children, it is necessary to know the epidemiology of pediatric respiratory failure. Randolph and coworkers (5) screened all mechanically ventilated children in nine pediatric ICUs over 6 months as part of a clinical trial. Of 6,403 total ICU admissions, 1,096 (17.1%) required mechanical ventilation for a minimum of 24 hours. Of ventilated children, 64% met exclusion criteria for trial enrollment such as upper airway obstruction or cyanotic congenital heart disease. Among children eligible for respiratory failure studies, 62% had acute pulmonary disease, 14% neurologic disease, and 9% cardiac disease. A chronic underlying condition was present in 43% of children. The most common diagnoses were bronchiolitis in infants (44%) and pneumonia in children of 1 year or older (25%). Mortality was 1.6% and median duration of ventilation was 7 days. The authors conclude that conducting clinical trials is feasible in critically ill children but the design needs to account for the underlying heterogeneity, infrequent mortality, and brief duration of mechanical ventilation. An editorial commentary by Cornfield and Haddad (6) accompanies this article.

In a critical care perspective, Bollen and colleagues (7) present a meta-analysis on use of high-frequency and conventional ventilation in premature neonates.

Respiratory Syncytial Virus Bronchiolitis
Cysteinyl-leukotrienes are released during infection with respiratory syncytial virus and may contribute to the bronchiolitis that commonly follows. Within 7 days of the onset of acute respiratory syncytial virus (RSV) bronchiolitis in 130 hospitalized infants (aged 3 to 36 months), Bisgaard and coworkers (8) did a 28-day randomized, double-blind trial of montelukast (5-mg chewable tablets) versus placebo. Symptoms during the day and night were absent in 22% of the infants treated with montelukast and in 4% of the infants receiving placebo. Daytime cough was reduced with montelukast. The authors conclude that regular treatment with montelukast, a leukotriene receptor antagonist, decreases the reactive airway disease that follows RSV bronchiolitis. An editorial commentary by Szefler and Simoes (9) accompanies this article.

In 88 babies who had at least one parent with atopy and asthma, Legg and coworkers (10) investigated the in vivo immune response to natural infection with RSV. Upper respiratory tract infection associated with RSV occurred in 28 infants, and 9 developed signs of acute bronchiolitis. Compared with infants with upper respiratory tract infection alone, the infants with acute bronchiolitis had an increased ratio of interleukin-4 to interferon-{gamma} in nasal lavage fluid on Days 1 and 2 and Days 5 to 7 of the illness; infants with acute bronchiolitis also had a higher ratio of interleukin-10 to interleukin-12 on days 1 and 2. Stimulated peripheral blood mononuclear cells revealed a decrease in messenger RNA levels for interleukin-18 and an increase in the ratio of interleukin-4 to interferon-{gamma} in the infants with acute bronchiolitis. The authors conclude that an excess of type 2 (Th2) helper T cell response and/or a deficiency of type 1 (Th1) helper T cell response contribute to the pathogenesis of RSV bronchiolitis. An editorial commentary by Lemanske (11) accompanies this article.

Sleep and Control of Breathing
To delineate the upper airway in children with sleep apnea, Arens and coworkers (12) did magnetic resonance and automatic segmentation in 20 children with obstructive sleep apnea and 20 control children. Compared with the control group, the children with sleep apnea had smaller airway volume (1,129 versus 1,794 mm3), and smaller mean cross-sectional area (28 versus 47 mm2) and smaller minimal cross-sectional area (4.6 versus 15.7 mm2) of the total airway. Segmental analysis revealed restriction throughout the initial two-thirds of the upper airway rather than in discrete regions adjacent to the adenoids or tonsils. Regional analysis revealed that the area was most restricted where the adenoids and tonsils overlapped. The authors conclude that the upper airway in children with obstructive sleep apnea has less volume and is narrower than in healthy children, and that restriction occurs throughout the initial two thirds of the airway and is greatest where the adenoids and tonsils overlap.

To determine the characteristics of arousal from sleep in infants who eventually die from sudden infant death syndrome (SIDS), Kato and coworkers (13) analyzed recordings obtained in 16 infants who had been studied some days or weeks before dying from SIDS. Compared with a control group of infants, the infants who later died of SIDS had less frequent cortical arousals (complete arousals) during both REM sleep (14.3 versus 23.1 per hour of sleep) and non-REM sleep (3.1 versus 3.6 per hour of sleep). Compared with the control group, the infants who later died of SIDS had more frequent subcortical activations (body movement without EEG change) during REM sleep (4.0 versus 1.4 per hour of sleep). The duration of subcortical activations was greater in the infants who later died of SIDS than in the control group (median duration, 7 versus 5 seconds). Compared with the control group, the infants who later died of SIDS had more frequent subcortical activations in the first part of the night (from 9:00 P.M. to 12:00 A.M.) and fewer cortical arousals during the later part of the night (from 3:00 A.M. to 6:00 A.M.) The authors conclude that infants who die from SIDS exhibit incomplete arousal processes during sleep in the weeks or months before their death. An editorial commentary by Harper (14) accompanies this article.

In 10 children with obstructive sleep apnea (apnea–hypopnea index, 8 events per hour) and 6 healthy children, Katz and White (15) studied genioglossus activity (intraoral surface electromyography) during wakefulness and sleep onset. During wakefulness, genioglossus activity was greater in patients than in control subjects (3.6 versus 1.6% of maximum). The decline in genioglossus activity during early and late sleep onset was greater in the patients. During stable non-REM sleep, activity of the genioglossus remained below the baseline value for wakefulness in all of the control children but increased above baseline in 4 of the 10 children with sleep apnea. The authors conclude that children with obstructive sleep apnea display increased activity of the genioglossus during wakefulness, probably as compensation for deficient pharyngeal anatomy.

To determine whether snoring is associated with poor academic performance in third-grade school children (mostly 9-year-olds), Urschitz and coworkers (16) studied 1,444 children by questionnaire and nocturnal home oximetry. Poor academic performance was a score of 4 to 6 (lowest quintile) on a 6-point scale (1 for outstanding, and 6 for failed). Snoring reported as "always" was associated with poor performance in mathematics (odds ratio, 3.6), science (odds ratio, 4.3), and spelling (odds ratio, 3.5). Snoring reported as "frequent" was associated with poor performance in mathematics (odds ratio, 2.4) and spelling (odds ratio, 2.0). Intermittent hypoxia did not show an independent association with poor academic performance. The authors conclude that habitual snoring is associated with poor academic performance in third-grade school children

To determine whether prenatal hypoxia leads to sustained modifications in ventilatory control and impairs the ability to learn a spatial task, Gozal and coworkers (17) exposed pregnant rats to intermittent hypoxia (10% oxygen concentration alternating with 21% oxygen every 90 seconds) or room air. At 5, 10, 15, and 30 days after delivery, newborn rats exposed to prenatal hypoxia had higher normoxic ventilation than did newborn rats exposed to prenatal room air. The peak ventilatory response to hypoxia at 5 days of age was depressed in rats exposed to prenatal hypoxia. Ventilatory equivalent (minute ventilation in relation to oxygen consumption) was decreased in rats exposed to prenatal hypoxia. The learning and memory of spatial tasks at one and four months was similar in rats exposed to prenatal hypoxia or normoxia. The authors conclude that gestational intermittent hypoxia leads to prolonged and irreversible alterations in respiratory control but does not produce obvious neurocognitive impairment.

Exposing an adult rat to intermittent hypoxia results in neurobehavioral impairment and increased apoptosis in the hippocampal CA1 region and cortex. In adult rats, Row and coworkers (18) examined whether intermittent hypoxia induces lipid peroxidation in cortical tissue and whether the latter is associated with neurocognitive impairment. Exposing adult rats to intermittent hypoxia (alternating 90-second periods of 10% oxygen and 21% oxygen) caused impairment of the ability to learn a spatial task (in a water maze). Twice-daily treatment with an antioxidant (PNU-101033E) attenuated the impairment in spatial learning. The antioxidant also attenuated the increase in lipid peroxidation and isoprostane concentration associated with intermittent hypoxia. The authors conclude that exposure to intermittent hypoxia induces oxidative stress, which is associated with behavioral impairment.

Pediatric Asthma
Epidemiology.
To determine the association between day care attendance in the first year of life and asthma and wheezing over the first six years of life, Celedon and coworkers (19) followed from birth 453 children with and without a maternal history of asthma. Day care in the first year of life was inversely associated with eczema (odds ratio, 0.3). Day care attendance in the first year of life was associated with a decreased risk of asthma (odds ratio, 0.3) and recurrent wheezing (odds ratio, 0.3) at 6 years of age, and with a decreased risk of wheezing after 4 years of age among children without a maternal history of asthma. Among children with a maternal history of asthma, day care in early life did not have a protective effect on asthma or recurrent wheezing at 6 years of age, but was instead associated with an increased risk of wheezing in the first 6 years of life. The authors conclude that a maternal history of asthma influences the relationship between day care–related exposure and childhood asthma.

To determine whether parasitic infection decreases the risk of wheeze in young children, Dagoye and coworkers (20) did a nested case-control study based on data on 7,155 children aged 1 to 4 years living in urban and rural areas of Ethiopia. Infections with parasites was common: Trichuris (54%), Ascaris (38%), and hookworm (10%). Wheezing in the past year was more prevalent in urban children than in rural children (4.4% versus 2%), and was less prevalent in children infected with Ascaris (adjusted odds ratio, 0.5). A similar, although nonsignificant, association was found for hookworm (adjusted odds ratio, 0.6), but not for Trichuris. Skin sensitization with Dermatophagoides pteronyssinus and cockroach (Blattella germanica) was more prevalent in rural than in urban children, and unrelated to wheeze. The authors conclude that Ascaris infection protects against wheeze in young Ethiopian children and that this effect is not mediated by inhibition of allergen sensitization.

Home dampness is associated with lower respiratory symptoms in children. To determine whether in-home fungal concentrations can predict lower respiratory illnesses (croup, pneumonia, bronchitis, and bronchiolitis) in the first year, Stark and coworkers (21) studied a prospective birth cohort of 499 children of parents with asthma/allergies. After controlling for sex, presence of water damage, presence of visible mold/mildew, a winter birth, breastfeeding, and exposure to other children (through siblings), multivariate analyses revealed significant associations between lower respiratory illnesses and high levels (more than 90th percentile) of airborne Penicillium (relative risk, 1.73), dust-borne Cladosporium (relative risk, 1.52), Zygomycetes (relative risk, 1.96), and Alternaria (relative risk, 1.51). On multivariate analysis, lower respiratory illnesses were associated with households that had any fungal level above the 90th percentile (relative risk, 1.86). The authors conclude that exposure to high levels of fungi in the home increase the risk of wheezing and nonwheezing lower respiratory illnesses during infancy.

Airway inflammation.
To assess the relationship between inflammatory mediators and clinical severity of asthma, La Grutta and coworkers (22) studied 17 children with moderate asthma, 12 children (steroid naive) with intermittent asthma, and 6 control children (overall age range, 8 to 13 years). Biomarkers were correlated with number of exacerbations over an 18-month follow-up period. Granulocyte/macrophage colony-stimulating factor released by peripheral blood mononuclear cells was higher in children with moderate and intermittent asthma than in control children; release of interleukin-8 was higher in children with moderate asthma than in children with intermittent asthma or control children. p65 nuclear factor-{kappa}B subunit and phosphorylated IkB{alpha} expression were greater in children with moderate asthma than in children with intermittent asthma or control children. Exhaled nitric oxide was equivalent in the three groups. Exacerbations were more frequent in children who were high producers of granulocyte/macrophage colony-stimulating factor, interleukin-8, and exhaled nitric oxide than in low producers. The authors conclude that several markers of inflammation are elevated in children with asthma. An editorial commentary by Warner (23) accompanies this article.

To characterize airway pathology in children with asthma, Barbato and coworkers (24) obtained bronchial biopsies in 9 children with asthma, 6 children with atopy and free of asthma, and 8 control children without asthma or atopy (ages ranged from 3 to 13 years). Thickness of the basement membrane and the number of eosinophils were increased in the children with asthma as compared with control subjects, but not when compared with atopic children. Children with asthma had decreased expression of receptor II for transforming growth factor-ß1 as compared with either the control children or atopic children. In the children with asthma, the number of eosinophils correlated negatively with receptor II for transforming growth factor-ß1 and positively with the duration of symptoms. The authors conclude that airway eosinophilia and thickening of the basement membrane are evident in children with mild asthma (and even in children with atopy but free of asthma), and that children with asthma (but not atopic children) exhibit downregulation of receptor II for transforming growth factor-ß1.

Because an imbalance between oxidant and antioxidants is implicated in the pathogenesis of asthma, Corradi and coworkers (25) obtained exhaled breath condensates in 12 children with an exacerbation of asthma (mean, 11 years). Malondialdehyde, an oxidant, was higher in children with asthma than in control subjects, 30.2 versus 19.4 nM; malondialdehyde was reduced to 18.5 nM by 5 days of prednisone. Glutathione, an antioxidant, was lower in children with asthma than in control children, 6.0 versus 14.1 nM; glutathione was increased to 8.4 nM after treatment with oral prednisone. In the overall group (both patients and control subjects), glutathione and malondialdehyde were negatively correlated (r = -0.50). The authors conclude that aldehydes and glutathione are measurable in exhaled breath condensates in children with asthma, and are modified by an acute exacerbation and by treatment with prednisone. An editorial commentary by Gaston (26) accompanies this article.

Remodeling of the airway wall occurs in adult patients with asthma and thickening of the reticular basement membrane is pathognomonic of asthma. Payne and coworkers (27) asked, "Do children with asthma display thickening of the reticular basement membrane?" They studied endobronchial biopsies from 19 children with difficult asthma, 10 children without asthma, 10 adults with mild asthma, 6 adults who had been intubated for life-threatening asthma, and 8 healthy adults. Thickness of the reticular basement membrane in children with asthma (median, 8.2 µm) was similar to that in adults with mild asthma (8.1 µm) and adults with life-threatening asthma (7.2 µm), and thicker than that in healthy children (4.4 µm) or healthy adults (4.9 µm). The authors conclude that thickening of the reticular basement membrane in children with difficult asthma is similar to that found in adults with asthma.

Treatment.
In 15 children aged 8 to 14 years, Agertoft and Pedersen (28) compared the lung deposition of budesonide inhaled from a Turbuhaler and fluticasone propionate inhaled from a Diskus. A secondary goal was to investigate whether the study design of pharmacokinetic studies could be simplified. When the two agents were administered on separate days, the mean lung deposition was 30.8% for the Turbuhaler and 8.0% for the Diskus. When the two agents were administered on the same day, the mean lung deposition was 29.5% for the Turbuhaler and 7.6% for the Diskus. The authors conclude that lung deposition is four times higher after inhalation of fluticasone propionate via a Turbuhaler than via a Diskus, and that it is possible to undertake pharmacokinetic studies by administering the two agents on the same day.

To determine the magnitude and predictors for hospital readmission for childhood asthma, Bloomberg and coworkers (29) analyzed data from 8,761 children who experienced 14,905 admissions for asthma. During the 10-year period, 30% of children were admitted more than once. A multivariate model revealed that African-American children with Medicaid or no insurance had a higher rate of readmission than did African-American children with commercial insurance or white (or other ethnicity) children regardless of insurance (risk ratio 1.28). The probability of readmission increased from 30% after the first admission to 46% after a second admission and to 59% after a third admission. The authors conclude that prior admission is a more powerful predictor for readmission for childhood asthma than are ethnicity, insurance status, or their combination.

Other Pediatric Issues
Air pollution.
In a cohort of children with asthma from 12 Southern California communities, McConnell and coworkers (30) investigated the relationship between bronchitic symptoms and ambient particulate matter, particulate elemental and organic carbon, nitrogen dioxide, and other gaseous pollutants. Symptoms (assessed by questionnaire every year between 1996 and 1999) were associated with yearly variability of particulate matter with aerodynamic diameter less than 2.5 µm (odds ratio, 1.41), nitrogen dioxide (odds ratio, 1.07), organic carbon (odds ratio, 1.41), nitrogen dioxide (odds ratio, 1.07), and ozone (odds ratio, 1.06). The within-community associations were stronger in magnitude than the between-community associations. The effects of yearly variation of organic carbon and nitrogen dioxide were only modestly reduced after adjusting for other pollutants. The effects of all other pollutants were reduced after adjusting for organic carbon and nitrogen dioxide. The authors conclude that previous cross-sectional studies may have underestimated the effects of organic carbon and nitrogen dioxide on chronic bronchitic symptoms in children with asthma.

Nicotinamide adenine dinucleotide (phosphate) reduced:quinone oxidoreductase (NQO1) and glutathione S-transferase (GST) M1 are detoxifying enzymes induced in response to oxidative stress, as occurs during ozone exposure. To examine the relationship between significant polymorphisms in NQO1 and GSTM1 and risk of asthma, David and coworkers (31) studied 218 case-parent triads in children from Mexico City (which has the highest ozone levels in North America). The Pro187Ser polymorphism in NQO1 was not associated with risk of asthma. Among subjects with homozygous deletion of GSTM1, carriers of a serine allele were at reduced risk of asthma as compared with Pro/Pro homozygotes. The authors conclude that children who live in an area with high exposure to ozone and who carry at least one NQO1 Ser allele and are homozygous for the GSTM1 deletion are at a decreased risk of asthma.

In utero exposure to cigarette smoke.
To determine whether in utero cigarette smoke has an effect on airway–alveolar structure, Elliott and coworkers (32) studied lungs from 32 infants who died from sudden infant death syndrome. The distance between alveolar attachments on the airways was greater in 16 infants who had been exposed to cigarette smoke both in utero and after birth (0.09 mm) and in 4 infants who have been exposed to cigarette smoke only in utero (0.10 mm) than in 8 infants without cigarette smoke exposure (0.08 mm) and in 4 infants who had only postnatal cigarette smoke exposure (0.4 mm). The percentage of elastin in the alveolar wall was similar in all groups. The authors conclude that exposure to in utero cigarette smoke causes abnormal airway function secondary to a reduction in the forces that oppose airway narrowing. An editorial commentary by Plopper and colleagues (33) accompanies this article.

To determine the independent and joint effects of in utero exposure to maternal smoking and age at diagnosis of asthma, Gilliland and coworkers (34) analyzed data on 5,933 participants in the Children's Health Study. Children exposed to cigarette smoke in utero, but without asthma, displayed decreases in FEV1/FVC, FEF25–75, and FEF25–75/FVC ratio. Among children exposed to smoke in utero, early onset of asthma was associated with larger decreases in FEV1, FEF25–75, and FEV1/FVC as compared with later diagnosed asthma. Children with both in utero exposure plus early onset asthma showed a 13.6% deficit in FEV1 and a 29.7% deficit in FEF25–75 among boys, and a 26.6% deficit in FEV1/FVC among girls. Exposure to environmental tobacco smoke alone had little effect. The authors conclude that deficits in lung function are greatest among children who are exposed to cigarette smoke in utero and who have an early onset of asthma.

Epidemiologic studies indicate that in utero exposure to cigarette smoke increases the risk of asthma in childhood, but the mechanism is unclear. To address this issue, Singh and coworkers (35) studied the effects of in utero smoke in mice. Animals exposed to smoke prenatally, but not postnatally, exhibited increased airway hyperresponsiveness to a single intratracheal injection of Aspergillus fumigatus extract. The increase in airway hyperresponsiveness was related to increased enzymatic activity of phosphodiesterase-4 and increased lung expression of messenger RNA for the phosphodiesterase-4D isoform. Hyperresponsiveness was not associated with increased leukocyte migration or mucus production. Exposure of adult mice to cigarette smoke did not alter airway hyperresponsiveness, levels of cyclic adenosine monophosphate, or phosphodiesterase activity. The authors conclude that prenatal exposure to cigarette smoke increases airway hyperresponsiveness by modulating levels of cyclic adenosine monophosphate through changes in the activity of phosphodiesterase-4D, and that these effects are independent of mucus production or leukocyte recruitment.

Maternal asthma.
Asthma during pregnancy is associated with low birth weight, but the mechanism is not known. To investigate the relationship, Murphy and coworkers (36) recruited 138 pregnant women with asthma and 44 pregnant women without asthma. Compared with the control group, mothers with asthma who did not use inhaled glucocorticoids give birth to lighter female infants (3,095 versus 3,528 g). The birth weight of male infants was equivalent in control mothers and mothers with asthma. The presence of a female fetus was associated with increased levels of circulating monocytes in mothers, decreased levels of 11ß-hydroxysteroid dehydrogenase type 2 in the placenta, decreased fetal plasma estriol, and a trend toward increased fetal plasma cortisol. The authors conclude that a female fetus has an adverse effect on the immune system of an asthmatic mother, which results in reduced fetal growth in mothers not receiving inhaled glucocorticoids.

Lung development.
To determine the effect of chorioamnionitis on gene expression in the preterm lung, Kallapur and coworkers (37) performed suppressive subtraction hybridization with messenger RNA at the peak of the inflammatory response to endotoxin. At 1 to 2 days after instillation of endotoxin into the amniotic fluid, the C-X-C chemokines, interferon-{gamma}-inducible 10-kD protein and monokine induced by interferon-{gamma}, were induced 30- to 40-fold in the fetal lung. The two chemokines were expressed focally in the bronchiolar epithelium, the peribronchiolar region, and the vascular endothelium. Messenger RNA for monokine induced by interferon-{gamma} was initially detected in infiltrating neutrophils, and later in bronchiolar areas, peribronchiolar areas, and vascular endothelium. Unlike endotoxin, administration of tumor necrosis factor-{alpha} or interleukin-1{alpha} into the amniotic fluid did not induce either of the C-X-C chemokines in the lung. Immunostaining revealed the receptors for the two chemokines in the peribronchiolar epithelium. The authors conclude that the angiostatic chemokines, interferon-{gamma}-inducible 10-kD protein and monokine induced by interferon-{gamma}, contribute to the lung injury and altered pulmonary vascular development in the preterm lamb exposed to chorioamnionitis.

In the developing cardiac, neural and mammary systems, differentiation induced by neuregulin-1 is based on cell-to-cell communication: the ligand neuregulin-1 is produced and secreted by one cell type (that does not express its receptors, erbB3 and erbB4) and acts on neighboring cell types (that do express these receptors). Dammann and coworkers (38) investigated the role of neuregulin-1 in fetal lung maturation. Immunostaining revealed increased neuregulin-1 in lung fibroblasts at the onset of surfactant synthesis. Neuregulin-1ß was secreted by fetal lung fibroblasts and stimulated synthesis of surfactant by type II cells. Neuregulin-1 and fetal lung fibroblast–conditioned media stimulated the phosphorylation of erbB2 receptor in type II cells. An antibody to neuregulin-1 blocked the effects of neuregulin-1 and fibroblast-conditioned media on both surfactant synthesis and phosphorylation of erbB2 receptor in type II cells. The authors conclude that neuregulin-1ß controls fetal lung maturation through mesenchymal–epithelial interactions in a paracrine mechanism.

Bronchopulmonary dysplasia.
Superoxide anion and other oxygen-free radicals have been implicated in the pathogenesis of bronchopulmonary dysplasia. To determine whether a catalytic antioxidant metalloporphyrin (AEOL 10113) can protect against oxygen toxicity, Chang and coworkers (39) studied baboons delivered 45 days prematurely. Compared with baboons given oxygen when needed, baboons receiving 100% oxygen had increased parenchymal mast cells and eosinophils, increased alveolar tissue volume, increased septal thickness, and decreased alveolar surface area. A continuous intravenous infusion of the antioxidant, AEOL 10113, partially reversed the oxygen-induced changes. Hyperoxia increased the number of neuroendocrine cells in the peripheral lung, which was preceded by increased levels of urine bombesin-like peptide at 48 hours of age. The increases in neuroendocrine cells and urine bombesin-like peptide were inhibited by the antioxidant. The authors conclude that a catalytic antioxidant metalloporphyrin (AEOL 10113) decreases the risk of oxygen toxicity in premature baboons. An editorial commentary by Tanswell and Jankov (40) accompanies this article.

In newborn mice exposed to hyperoxia, Ahmed and coworkers (41) determined whether targeted overexpression of human extracellular superoxide dismutase would promote normal lung development. Newborn transgenic mice and wild-type mice were exposed to 95% oxygen or air for 7 days. Activity of extracellular superoxide dismutase was 2.5 times greater in the transgenic mice than in the control mice. At 7 days, the transgenic mice had less pulmonary neutrophil influx and oxidized glutathione than did the control mice. After 14 days of exposure to 60% oxygen, transgenic mice had greater preservation of alveolar surface and volume density than did the control mice. The authors conclude that overexpression of human extracellular superoxide dismutase protects newborn mice against hyperoxia-induced inflammation at 7 days and impairment of lung development at 21 days.

To determine the role of fibroblast growth factor receptor-1 in compensatory lung growth after hyperoxic exposure, Jankov and coworkers (42) exposed neonatal rats to 95% oxygen for 7 days after birth. The rats showed inhibited lung growth, DNA synthesis, and secondary septation, all of which recovered during a period of air breathing. Expression of basic fibroblast growth factor was reduced at the end of 7 days of 95% oxygen; it increased after 3 days of recovery in air. Expression of fibroblast growth factor receptor-1 was not affected by hyperoxia or recovery in air. The role of fibroblast growth factor in the compensatory lung growth after discontinuation of hyperoxia was further evaluated by injecting (intraperitoneally) soluble truncated fibroblast growth factor receptor-1 at the onset of the recovery phase. (The truncated receptor acts as a decoy for the natural receptor ligands, which are then no longer available to bind to the endogenous receptor.) The truncated receptor arrested compensatory lung DNA synthesis and secondary septation. The authors conclude that the compensatory lung growth and septation in neonatal rats experiencing growth arrest secondary to hyperoxia is in part mediated by fibroblast growth factor receptor-1.

Bombesin-like peptides are elevated in newborns that go on to develop bronchopulmonary dysplasia, and blocking these peptides abrogates bronchopulmonary dysplasia in baboons. Subramaniam and coworkers (43) determined whether bombesin-like peptides function postnatally as proinflammatory cytokines. In mice, intratracheal administration of bombesin induced increased numbers of mast cells after 48 hours. The mast cells revealed messenger RNAs encoding bombesin receptor subtype 3 and neuromedin-B receptor, but not gastrin-releasing peptide receptor. Only neuromedin-B receptor null mice accumulated fewer mast cells in the lungs after treatment with bombesin. In vitro studies revealed that bombesin, gastrin-releasing peptide, neuromedin-B receptor, and a bombesin receptor subtype 3–specific ligand induced proliferation of mast cells and chemotaxis. The authors conclude that multiple bombesin-like peptides promote mast cell responses and contribute to the development of bronchopulmonary dysplasia.

The American Thoracic Society (44) presents a statement on care of the child with chronic lung disease of infancy and childhood.

In a state of the art review article, Kinnula and Crapo (45) discuss superoxide dismutase in lung disease.

Infections and sepsis.
To characterize the epidemiology of sepsis in children, Watson and coworkers (46) analyzed data on 1,586,253 hospitalizations in children, 19 years or younger. There were 42,364 cases of severe sepsis per year nationally in children (0.56 cases per 1,000 population per year). Incidence was highest in infants (5.2 per 1,000), lower in 10- to 14-year-old children (0.2 per 1,000), and 15% higher in boys than in girls. Half the cases had an underlying disease, and 23% were low-birth-weight newborns. The most common infections were respiratory (37%) and primary bacteremia (25%). Hospital mortality was 10.3%, mean length of stay was 31 days, and cost was $40,600. Annual costs were estimated at $1.97 billion nationally. The authors conclude that there are more than 42,000 cases of sepsis with 4,400 associated deaths in the United States each year.


    SURFACTANT BIOLOGY AND DISORDERS
 TOP
 CONTENTS
 PEDIATRICS
 SURFACTANT BIOLOGY AND DISORDERS
 CYSTIC FIBROSIS
 REFERENCES
 
Pathophysiology
Keratinocyte growth factor induces transient proliferation of alveolar type II cells associated with alterations of surfactant. To determine the effect of keratinocyte growth factor on homeostasis of surfactant, Fehrenbach and coworkers (47) studied lung tissue from adult rats after intratracheal instillation of recombinant human keratinocyte growth factor or phosphate-buffered saline. Compared with saline, keratinocyte growth factor produced a 3.6-fold increase in coverage of alveolar walls by type II cells, a 1.7-fold increase in the number of type II cells per ml of lung volume, a 44% decrease in the number of lamellar bodies per cell, and a 54% decrease in the volume of lamellar bodies per cell (although the total amount of lamellar bodies per ml of lung volume did not change). There was a parallel shift to larger lamellar bodies. Keratinocyte growth factor led to an increase in radiolabeled phospholipids in whole lung tissue (relative to lavage fluid), although less radiolabel was incorporated per cell. The authors conclude that proliferation of alveolar type II cells induced by keratinocyte growth factor is accompanied by a decrease in surfactant within a unit cell, although the amount of surfactant per unit lung volume remains constant.

The hydrophobic surfactant protein C binds to lipopolysaccharide (which is found in airborne particles) and one of its cellular receptors, CD14. Augusto and coworkers (48) investigated the influence of surfactant protein C on the responses of immunocompetent cells to lipopolysaccharide. When associated with vesicles of dipalmitoylphosphatidylcholine, surfactant protein C inhibited the mitogenic effect of lipopolysaccharide to a macrophage cell line (RAW 264.7). Under similar conditions, surfactant protein C inhibited the mitogenic effect of lipopolysaccharide on mouse splenocytes, inhibited the lipopolysaccharide-induced production of tumor necrosis factor-{alpha} by peritoneal and alveolar macrophages, and of nitric oxide by the macrophage cell line. In contrast, surfactant protein C did not affect production of tumor necrosis factor-{alpha} induced by a lipopeptide or production of nitric oxide induced by picolinic acid. The lipopolysaccharide-binding capacity of surfactant protein C was resistant to peroxynitrite (a known mediator of acute lung injury formed by the reaction of nitric oxide with superoxide anions). The authors conclude that surfactant protein C resists degradation under inflammatory conditions and traps lipopolysaccharide, preventing it from inducing the production of noxious mediators in alveolar cells.

Surfactant inhibits the synthesis of type IIA secretory phospholipase A2 by alveolar macrophages. Wu and coworkers (49) sought to determine the components of surfactant involved in this inhibition, and the associated signaling pathways. Expression of type IIA secretory phospholipase A2 by alveolar macrophages (stimulated by endotoxin) was inhibited by both surfactant protein-A and the surfactant phospholipid fraction. Expression of the enzyme was abolished by surfactant phospholipid dioleylphosphatidylglycerol, but not by dipalmitoylphosphatidylcholine. Phosphatidylglycerol was rapidly incorporated and metabolized by alveolar macrophages and its metabolites accumulated in the cytosol. Nuclear factor-{kappa}B modulated the expression of type IIA secretory phospholipase A2 by endotoxin-stimulated alveolar macrophages, and the latter effect was suppressed by surfactant phospholipid fraction, surfactant protein-A, and dioleylphosphatidylglycerol. The authors conclude that surfactant protein-A and dioleylphosphatidylglycerol modulate the inhibition of type IIA secretory phospholipase A2 expression (in alveolar macrophages) and the inhibition occurs by downregulating the activation of nuclear factor-{kappa}B.

Deficiency
Marttila and coworkers (50) investigated the interaction between genetic variants of surfactant protein-A and surfactant protein-B as determinants of respiratory distress syndrome. DNA samples from 441 premature singleton infants and 480 twin or multiple infants were genotyped for surfactant protein-A1, -A2, and -B exon 4 polymorphisms and intron 4 size variants in a homozygous white population. Surfactant protein-A1 allele 6A2 and homozygous genotype 6A2/6A2 were overrepresented in singletons with respiratory distress syndrome when the surfactant protein-B genotype was Thr/Thr, and underrepresented in multiples with respiratory distress syndrome when surfactant protein-B genotype was Ile/Thr or Thr/Thr. The surfactant protein-A 6A2 allele in the surfactant protein-B Thr131 background predisposed the smallest singleton infants to respiratory distress syndrome, whereas near-term multiples were protected from respiratory distress syndrome. Labeled lung explants with the Thr/Thr genotype showed prosurfactant protein-B amino-terminal glycosylation, which was absent in the Ile/Ile samples. The authors conclude that genetic variants of two surfactant proteins, intertwined with environmental factors, influence susceptibility to respiratory distress syndrome.

To assess the postnatal profile of surfactant proteins, Ballard and coworkers (51) collected tracheal aspirates from 35 intubated infants of 23 to 31 weeks of gestation and between 8 and 80 days of age. In 71 large aggregate surfactant samples, the content of surfactant protein-A was 7.1% of phospholipids, content of surfactant protein-B was 1.8% of phospholipid, and content of surfactant protein-C was 4.6% of phospholipid. On the second day of life, content of surfactant protein-A was 13.4%, content of surfactant protein-B was 8.4%, and content of surfactant protein-C was 0.1% of the mean levels for the samples obtained between the eight to eightieth day. The major postnatal increases occurred during the first week for surfactant protein-A, the second week for surfactant protein-B, and third week for surfactant protein-C. The authors conclude that newborn premature infants of less than 32 weeks of gestation have low concentrations of surfactant protein-A and surfactant protein-B and extremely low values of surfactant protein-C, and that the three proteins have different postnatal development profiles.

Treatment
Therapeutic lung lavage is an emerging treatment for meconium aspiration pneumonia. In 2-week-old piglets with experimental meconium aspiration, Dargaville and coworkers (52) investigated the type of fluid, and at what volume, would be most effective for lavage. Compared with a control (nonlavaged) group, lavage with 30 ml per kg of dilute bovine surfactant or a perfluorocarbon emulsion improved oxygenation. Sustained decrease in alveolar–arterial oxygen difference at 5 hours was achieved only with dilute surfactant (250 mm Hg), and not with perfluorocarbon emulsion (460 mm Hg) or no lavage (460 mm Hg). The surfactant group exhibited less lung injury on histology and biochemistry. In additional studies, administration of two aliquots of 15 ml per kg was more effective than administration of ten aliquots of 3 ml per kg. The authors conclude that use of two aliquots of surfactant (15 ml per kg) is effective in decreasing lung injury in piglets with meconium aspiration. An editorial commentary by Kinsella (53) accompanies this article.

In 40 patients with ARDS, Spragg and coworkers (54) did a phase I/Phase II randomized trial of a recombinant surfactant protein C–based surfactant (Venticute). Patients received one or two doses of exogenous surfactant on four occasions over 24 hours. Treatment was well tolerated. No benefit was noted. At 48 hours, bronchoalveolar lavage reflected exogenous surfactant components, did not show improvement in lowering of surface tension, and had lower level of interleukin-6 than did the control group. Exogenous surfactant was not detected in lavage fluid at 120 hours. The authors conclude that a recombinant protein C–based surfactant can be safely administered to patients with acute lung injury.


    CYSTIC FIBROSIS
 TOP
 CONTENTS
 PEDIATRICS
 SURFACTANT BIOLOGY AND DISORDERS
 CYSTIC FIBROSIS
 REFERENCES
 
Genetics
To determine whether polymorphisms of certain inflammatory mediator and regulatory genes influence organ damage in patients with cystic fibrosis (CF), Arkwright and coworkers (55) studied 261 patients. Ultrasound features of hepatic cirrhosis were more frequent in the high-producer (DD) than in the low-producer (II) genotype for angiotensin I–converting enzyme. The age at which FEV1 reached below 50% of predicted was associated with the high-producer DD genotype (odds ratio, 2.3), transforming growth factor-ß1 genotype (odds ratio, 2.6), and the age at which Pseudomonas aeruginosa first colonized the sputum (odds ratio, 9.1). The authors conclude that the high-producer genotype (DD) for angiotensin I–converting enzyme is associated with portal hypertension and early onset of pulmonary dysfunction in patients with CF. An editorial commentary by Accurso and Sontag (56) accompanies this article.

In 70 patients with CF (aged 4 to 40 years with an FEV1 of 69% of predicted), Grasemann and coworkers (57) determined whether the 894G/T variant in exon 7 of the gene for endothelial nitric oxide synthase was related to exhaled nitric oxide and lung function. Exhaled nitric oxide was higher in female patients with an 894T mutant allele than in female patients who were homozygous for the 894G wild-type allele (7.0 versus 3.6 parts per billion); no such association was seen in male patients. Among female patients, colonization of the airways with Pseudomonas aeruginosa was more frequent among homozygotes with the 894G wild-type allele than among carriers of the 894T mutant allele: 69 versus 31%. The authors conclude that the 894T variant in the gene for endothelial nitric oxide synthase is associated with increased formation of nitric oxide in female patients with CF, possibly influencing airway colonization with Pseudomonas aeruginosa. An editorial commentary by Accurso and Sontag (56) accompanies this article.

Lung Inflammation
Leukotriene B4 is a potent chemoattractant of neutrophils and it induces oxygen-free radical generation. Interleukin-6 is a cytokine with both inflammatory and anti-inflammatory actions. Carpagnano and coworkers (58) determined whether measurements of these two markers could be used to monitor airway inflammation in patients with CF. Compared with 15 healthy subjects, 20 patients experiencing an acute exacerbation of CF (aged 28 years) had higher levels of leukotriene B4 (28.8 versus 6.8 pg per ml) and interleukin-6 (8.7 versus 2.6 pg per ml). In 6 patients, antibiotic treatment produced decreases in exhaled leukotriene B4 (31.1 to 18.8 pg per ml) and interleukin-6 (9.5 to 6.4 pg per ml). Compared with 5 patients who were infected with other bacteria, 15 patients who were infected with Pseudomonas aeruginosa had higher levels of leukotriene B4 (34.3 versus 18.3 pg per ml) and interleukin-6 (9.3 versus 6.9 pg per ml). The authors conclude that measurement of leukotriene B4 and interleukin-6 in exhaled breath condensates may prove useful in monitoring airway inflammation in patients with airway inflammation.

The collectins, surfactant protein-A and surfactant protein-D, enhance opsonization of microbes and limit the lung inflammatory response. To assess the relationship between collectins, bacteria, and inflammation, Noah and coworkers (59) performed bronchoalveolar lavage in 46 children with CF and 31 patients without CF. Children with CF had more neutrophils relative to bacteria than did the control group. Surfactant protein-A tended to be lower in the patients with CF, although the decrease was significant only when bacterial infection was present. The concentration of surfactant protein-A was inversely related to inflammation, number of bacterial colony-forming units, and age. Children with CF had decreased levels of surfactant protein-D, and the levels were rarely detectable when infection was present. Autopsy specimens also revealed a paucity of surfactant protein-A and surfactant protein-D at sites of infection and inflammation. The authors conclude that inflammation induced by chronic infection in relatively young children with CF is linked to a marked deficiency of surfactant protein-D and age-related decline of surfactant protein-A.

Microbiology
To determine the prevalence of nontuberculous mycobacteria and clinical features in patients with CF, Olivier and coworkers (60) did a prospective cross-sectional study at 21 U.S. centers. The prevalence of nontuberculous mycobacteria in sputum was 13%. The most common species were Mycobacterium avium complex (72%) and Mycobacterium abscessus (16%). Compared with culture-negative patients, the culture-positive patients were older (26 versus 22 years), had a higher FEV1 (60 versus 54%), higher frequency of Staphylococcus aureus (43 versus 31%), and lower frequency of Pseudomonas aeruginosa (71 versus 82%). Molecular typing revealed unique strains in almost all patients. The authors conclude that nontuberculous mycobacteria are common in patients with CF, and that person-to-person spread or nosocomial acquisition does not explain the higher acquisition. An editorial commentary by Griffith (61) accompanies this article.

To determine the short-term effect of nontuberculous mycobacteria on the clinical course of patients with CF, Olivier and coworkers (62) followed 60 incident-positive and 99 culture-negative patients for 15 months. The annual rate of decline in FEV1 was 5% in patients who met ATS criteria for nontuberculous mycobacteria disease, 3% in culture-positive patients not meeting the ATS criteria, and 3% in control subjects. Two or more characteristic findings on high-resolution computed tomography were seen in 60% patients with three or more positive cultures, in 32% of patients two or fewer positive cultures, and in 19% of patients with negative cultures. Progression of changes on computed tomography was seen in all of the patients with three or more positive cultures. The authors conclude that multiple positive cultures for nontuberculous mycobacteria in patients with CF predict progressive changes on computed tomography without affecting FEV1. An editorial commentary by Griffith (61) accompanies this article.

Pathophysiology and Exercise Performance
To determine the relationship between respiratory and limb muscle mass, strength, and nutritional impairment, Pinet and coworkers (63) studied 18 patients with CF (mean age, 28 years) and 15 healthy subjects. Lean body mass, quadriceps strength, and quadriceps cross-section were lower in patients with CF. Twitch transdiaphragmatic pressure was 23% lower and twitch gastric pressure was 22% higher in the patients than in the control subjects. Diaphragmatic mass and abdominal muscle thickness were equivalent in the patients and control subjects. For any given lean body mass, however, diaphragmatic mass and abdominal wall thickness were greater in the patients than in the control subjects. Intersubject variability in diaphragmatic mass was greater in the patients than in the control subjects. The authors conclude that patients with CF have decreased muscle bulk of the quadriceps but not of the diaphragm and abdominal wall, and decreased strength of the diaphragm but increased strength of the abdominal muscles, suggesting a respiratory muscle training effect in at least some patients. An editorial commentary by Maltais (64) accompanies this article.

To determine the pathophysiology of impaired exercise tolerance in patients with CF, Selvadurai and coworkers (65) studied 16 girls with mild CF (age 15 years) participating in elite sports and a control group of 16 female teammates without CF; FEV1 was respectively 96% and 98% of predicted. Compared with the control group, resting energy expenditure was 7.6% higher and habitual daily activity was 15% higher in the CF group. Peak aerobic capacity was equivalent in the two groups. Peak anaerobic power was 20% lower in the CF Group. 31P magnetic resonance spectroscopy revealed no difference between the groups at rest. At 25% of total work output, the CF group was less acidotic than was the control group (pH 6.99 versus 6.90) and had a lower ratio of inorganic phosphorus to phosphocreatine (0.34 versus 0.41). The differences between the groups continued to increase until maximum exercise. The authors conclude that girls with mild CF who are exercising on a treadmill have intrinsic metabolic defects in skeletal muscle, decreased anaerobic power, and leg strength despite having normal lung function and good nutritional status.

To determine whether quantification of aerobic fitness is helpful in predicting disability, Frangolias and coworkers (66) studied 73 patients with CF (aged 30 years). Disability was associated with FEV1, maximal oxygen consumption, Schwachman-Kulczycki clinical score, Brasfield radiology score, and frequency of exacerbations. Disability was not associated with change in FEV1 over 2 years or with oxygen saturation at rest or during exertion. The best independent predictors of disability were FEV1 and the Schwachman-Kulczycki score. The authors conclude that FEV1 and the Schwachman-Kulczycki score predict limitation of patients with CF in a work or school environment, and that other physiological and clinical measures do not predict limitation.

In 25 children with CF randomized to one-year treatment with daily dornase alfa (Pulmozyme) or normal saline, Robinson and coworkers (67) investigated the relative ability of variables derived from pulmonary function measurements and high-resolution computed tomography in detecting an intervention effect. At 12 months, the greatest change from baseline was obtained with a composite total computed tomography score that also incorporated pulmonary function (35.4%) and a composite maximal computed tomography score that incorporated pulmonary function (30.4%). These changes are contrasted with the change in FEF25–75% (13.0%), total global computed tomography (6.2%), and maximal global computed tomography (7.2%). The authors conclude that composite scores that incorporate both pulmonary function and high-resolution computed tomography are superior to other measures for detecting a treatment effect with dornase alfa in children with CF.

Abnormal ion transport is a fundamental defect in cystic fibrosis. To determine whether airway ion transport is related to severity of lung disease, Wallace and coworkers (68) measured nasal potential difference in 51 patients with CF (age range, 5.9 to 17.7 years). No correlation was observed between any measurement of ion transport and several measures of clinical status. Of 30 patients homozygous for the {Delta}F508 mutation, ion transport variables did not differ between patients whose pulmonary function was above or below the average level of function. Ten patients had significant hyperpolarization (greater than 5 mV) after perfusion with a zero chloride solution; chloride secretory capacity did not correlate with above average lung function. The authors conclude that the degree of abnormal ion transport in patients with CF is not correlated with severity of lung disease.

The response of nasal potential difference to perfusion solutions provides a convenient surrogate marker of the defect in movement of chloride across the epithelium, a characteristic abnormality in CF. In seven patients with CF, Middleton and coworkers (69) did sequential perfusions (on different days) with amiloride, low chloride, and isoproterenol, with diluents containing different concentrations of calcium and magnesium. With diluents nominally free of calcium, the low-chloride responses were 8.0, 8.6, and 9.6 millivolts at magnesium concentrations of 0, 1, and 3 mM, respectively; these responses were significantly different from the responses in the presence of divalent ions. The subsequent response to isoproterenol did not differ between the presence or absence of divalent ions. The authors conclude that perfusion of the CF airway with nominally calcium-free solutions reduces tonic inhibition of chloride secretion.

In 20 patients with stable CF (aged 13.5 years) and 33 healthy subjects, Terheggen-Lagro and coworkers (70) investigated the relationship between measurements of end-tidal carbon monoxide and lung volume. End-tidal carbon monoxide did not differ between the patients and the control group: 1.2 versus 1.3 ppm. In the control group, end-tidal carbon monoxide was correlated with lung volume (r = 0.64) and with diffusing capacity for carbon monoxide (r = 0.48). When corrected for differences in total lung capacity, the level of end-tidal carbon monoxide was higher in the patients than in the control group: 143 versus 100%. The authors conclude that the level of end-tidal carbon monoxide is equivalent in patients with CF and healthy subjects but higher in the patients when the level is corrected for lung volume.

Treatment
Gene therapy.
The human polymeric immunoglobulin receptor is expressed at high levels in the airway epithelium and is adapted for uptake and nondegradative transfer of polymeric antibodies to the luminal surface of epithelia. Because neutrophil elastase contributes to the progression of lung disease in patients with CF, Ferkol and coworkers (71) developed a strategy for delivering antiproteases to inaccessible CF airways via the immunoglobulin receptor. A fusion protein consisting of a single-chain Fv antibody (directed at the extracellular domain of the immunoglobulin receptor or human secretary component) linked to human {alpha}1-antitrypsin is carried across human tracheal xenografts (in mice); more antiprotease is delivered to the apical surface than achieved by passive diffusion alone. Targeted delivery of the antiprotease paralleled the expression of the human polymeric immunoglobulin receptor in vivo. Delivery was not increased by increasing doses, indicating that airway penetration was receptor dependent, not dose-dependent. The authors conclude that a strategy based on a fusion-protein can deliver therapeutic agents, such as antiproteases, to the luminal surface of respiratory epithelium, beneath the mucus layer and within the airway surface fluid.

Richard and coworkers (72) investigated the reliability of positron emission tomographic imaging in detecting the expression of genes delivered to the lungs by viral vectors. The study was conducted in normal rats and an enhanced mutant herpes simplex virus-1 thymidine kinase was used as the reporter gene. Rats were studied 3 days after the intratracheal administration of a replication-incompetent adenovirus containing a fusion gene for the mutant kinase and green fluorescent protein. The rats were injected with an imaging substance for the viral kinase, 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine; images were obtained one hour later. Measurements derived from imaging were linearly correlated with measures of thymidine kinase activity and green fluorescent protein levels in tissue (r2 = 0.96). Imaging detected expression of thymidine kinase in 15 of 16 rats, even at low viral doses. Imaging for the viral kinase was correlated with in vitro assays for both kinase activity (r2 = 0.48) and fluorescent protein (r2 = 0.46). The authors conclude that positron emission tomographic imaging is a sensitive and quantitative method for noninvasive detection of pulmonary reporter gene expression.

Mucolytic agents.
In 16 healthy subjects, Sood and coworkers (73) studied the relationship between acute increases in airway surface liquid and mucociliary clearance. Inhalation of increasing concentrations of saline (0.12, 0.9, and 7%) produced a twofold increase in mucociliary clearance in the whole and peripheral lung. Amiloride (a sodium-channel blocker that increases airway surface liquid) produced a twofold increase in mucociliary clearance after inhalation of 0.12 and 0.9% saline, but not after inhalation of 7% saline. Pretreatment with amiloride or inhalation of 7% saline alone increased the rate of mucociliary clearance to that seen in systemic pseudohypaldosteronism (a condition where impaired function of the sodium channel produces an increase in airway surface liquid). The authors conclude that measures that increase the volume of airway surface liquid produce increased mucociliary clearance in healthy subjects.

Antibiotic therapy.
To determine whether inhaled tobramycin eradicates Pseudomonas aeruginosa from the lower airways of young children (6 months to 6 years) with CF, Gibson and coworkers (74) did a double-blind, placebo-controlled trial. The trial was stopped after 21 of the expected 98 subjects were studied because of significant benefit. Bronchoalveolar lavage on day 28 revealed eradication of Pseudomonas aeruginosa in 100% of patients in the tobramycin group and in 7.4% of patients in the placebo group. The groups did not differ in clinical indices, markers of inflammation, or incidence of side effects. The authors conclude that 28 days of inhaled tobramycin (300 mg twice daily) is safe and effective in decreasing the density of Pseudomonas aeruginosa in the lower airways of children with CF.

To assess the usefulness of markers of infection and inflammation in assessing the response to antibiotic therapy in CF, Ordonez and coworkers (75) obtained induced sputum in 55 patients with CF before and after treatment with intravenous antibiotics. Antibiotic therapy produced decreases in the density of Pseudomonas aeruginosa (by 2.4 log10 cfu per gram), and Staphylococcus aureus (by 4.0 log10 cfu per gram), decrease in neutrophil count (by 0.4 log10 cells per ml), decrease in interleukin-8 (by 0.5 log10 pg per ml), decrease in neutrophil elastase (by 0.4 log10 µg per ml), and an increase in FEV1 (by 0.3 liter). Of the 127 sputum induction procedures, 7 (6%) were accompanied by a decrease in FEV1 of 20% or more. The authors conclude that antibiotic treatment of a pulmonary exacerbation of CF results in improvements in FEV1 and several markers in induced sputum (namely, decreases in P. aeruginosa and S. aureus density, neutrophil count, interleukin-8 concentration, and neutrophil elastase activity). An editorial commentary by Armstrong (76) accompanies this article.

In a state of the art review article, Gibson and colleagues (77) discusses the pathophysiology and management of infections in CF.

In a clinical commentary, Tan and colleagues (78) discuss the use of aminoglycosides in the management of patients with CF.

Outcome.
To determine whether early diagnosis of CF leads to improved pulmonary outcome, Farrell and coworkers (79) did a randomized trial in 103 patients. The diagnosis was made at 12.4 weeks in the 56 patients in the screening group and at 95.8 weeks in the 47 patients in the standard group. Pulmonary function and chest radiography were compared when the youngest patient was 7 years old. The first chest radiograph exhibited fewer abnormalities in the screened group, but the groups converged over time. After 10 years of age, the screened group had worst chest radiograph scores associated with earlier acquisition of Pseudomonas aeruginosa. Abnormalities of pulmonary function, which were generally mild, did not differ between the groups. The authors conclude that neonatal screening for CF does not result in improved pulmonary outcome.


    FOOTNOTES
 
Supported by a Merit Review grant from the Veterans Affairs Research Service.

Conflict of Interest Statement: M.J.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.


    REFERENCES
 TOP
 CONTENTS
 PEDIATRICS
 SURFACTANT BIOLOGY AND DISORDERS
 CYSTIC FIBROSIS
 REFERENCES
 

  1. Gauld LM, Kappers J, Carlin JB, Robertson CF. Prediction of childhood pulmonary function using ulna length. Am J Respir Crit Care Med 2003;168:804–809.[Abstract/Free Full Text]
  2. Hulskamp G, Hoo AF, Ljungberg H, Lum S, Pillow JJ, Stocks J. Progressive decline in plethysmographic lung volumes in infants: physiology or technology? Am J Respir Crit Care Med 2003;168:1003–1009.[Abstract/Free Full Text]
  3. Jones MH, Howard J, Davis S, Kisling J, Tepper RS. Sensitivity of spirometric measurements to detect airway obstruction in infants. Am J Respir Crit Care Med 2003;167:1283–1286.[Abstract/Free Full Text]
  4. Beydon N, Pin I, Matran R, Chaussain M, Boule M, Alain B, Bellet M, Amsallem F, Alberti C, Denjean A, et al. Pulmonary function tests in preschool children with asthma. Am J Respir Crit Care Med 2003;168:640–644.[Abstract/Free Full Text]
  5. Randolph AG, Meert KL, O'Neil ME, Hanson JH, Luckett PM, Arnold JH, Gedeit RG, Cox PN, Roberts JS, Venkataraman ST, et al. The feasibility of conducting clinical trials in infants and children with acute respiratory failure. Am J Respir Crit Care Med 2003;167:1334–1340.[Abstract/Free Full Text]
  6. Cornfield DN, Haddad IY. A rose by any other name is yet a rose: acute respiratory failure in children. Am J Respir Crit Care Med 2003;168:268–269.[Free Full Text]
  7. Bollen CW, Uiterwaal CS, Van Vught AJ. Cumulative metaanalysis of high-frequency versus conventional ventilation in premature neonates. Am J Respir Crit Care Med 2003;168:1150–1155.[Free Full Text]
  8. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167:379–383.[Abstract/Free Full Text]
  9. Szefler SJ, Simoes EA. Montelukast for respiratory syncytial virus bronchiolitis: significant effect or provocative findings? Am J Respir Crit Care Med 2003;167:290–291.[Free Full Text]
  10. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003;168:633–639.[Abstract/Free Full Text]
  11. Lemanske RF Jr. Does respiratory syncytial viral-induced bronchiolitis result from helper T cell type 1/type 2 cytokine imbalance? Am J Respir Crit Care Med 2003;168:625–627.[Free Full Text]
  12. Arens R, McDonough JM, Corbin AM, Rubin NK, Carroll ME, Pack AI, Liu J, Udupa JK. Upper airway size analysis by magnetic resonance imaging of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2003;167:65–70.[Abstract/Free Full Text]
  13. Kato I, Franco P, Groswasser J, Scaillet S, Kelmanson I, Togari H, Kahn A. Incomplete arousal processes in infants with sudden death. Am J Respir Crit Care Med 2003;168:1298–1303.[Abstract/Free Full Text]
  14. Harper RM. Impaired arousals and sudden infant death syndrome: preexisting neural injury? Am J Respir Crit Care Med 2003;168:1262–1263.[Free Full Text]
  15. Katz ES, White DP. Genioglossus activity in children with obstructive sleep apnea during wakefulness and sleep onset. Am J Respir Crit Care Med 2003;168:664–670.[Abstract/Free Full Text]
  16. Urschitz MS, Guenther A, Eggebrecht E, Wolff J, Urschitz-Duprat PM, Schlaud M, Poets CF. Snoring, intermittent hypoxia and academic performance in primary school children. Am J Respir Crit Care Med 2003;168:464–468.[Abstract/Free Full Text]
  17. Gozal D, Reeves SR, Row BW, Neville JJ, Guo SZ, Lipton AJ. Respiratory effects of gestational intermittent hypoxia in the developing rat. Am J Respir Crit Care Med 2003;167:1540–1547.[Abstract/Free Full Text]
  18. Row BW, Liu R, Xu W, Kheirandish L, Gozal D. Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. Am J Respir Crit Care Med 2003;167:1548–1553.[Abstract/Free Full Text]
  19. Celedon JC, Wright RJ, Litonjua AA, Sredl D, Ryan L, Weiss ST, Gold DR. Day care attendance in early life, maternal history of asthma, and asthma at the age of 6 years. Am J Respir Crit Care Med 2003;167:1239–1243.[Abstract/Free Full Text]
  20. Dagoye D, Bekele Z, Woldemichael K, Nida H, Yimam M, Hall A, Venn AJ, Britton JR, Hubbard R, Lewis SA. Wheezing, allergy, and parasite infection in children in urban and rural Ethiopia. Am J Respir Crit Care Med 2003;167:1369–1373.[Abstract/Free Full Text]
  21. Stark PC, Burge HA, Ryan LM, Milton DK, Gold DR. Fungal levels in the home and lower respiratory tract illnesses in the first year of life. Am J Respir Crit Care Med 2003;168:232–237.[Abstract/Free Full Text]
  22. La Grutta S, Gagliardo R, Mirabella F, Pajno GB, Bonsignore G, Bousquet J, Bellia V, Vignola AM. Clinical and biological heterogeneity in children with moderate asthma. Am J Respir Crit Care Med 2003;167:1490–1495.[Abstract/Free Full Text]
  23. Warner JO. The blood lung function test: does it exist for asthma? Am J Respir Crit Care Med 2003;167:1465–1466.[Free Full Text]
  24. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Tura M, Zuin R, Beghe B, Maestrelli P, Fabbri LM, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003;168:798–803.[Abstract/Free Full Text]
  25. Corradi M, Folesani G, Andreoli R, Manini P, Bodini A, Piacentini G, Carraro S, Zanconato S, Baraldi E. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am J Respir Crit Care Med 2003;167:395–399.[Abstract/Free Full Text]
  26. Gaston B. Breath condensate analysis: perhaps worth studying, after all. Am J Respir Crit Care Med 2003;167:292–293.[Free Full Text]
  27. Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, Jeffery PK. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003;167:78–82.[Abstract/Free Full Text]
  28. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler in children. Am J Respir Crit Care Med 2003;168:779–782.[Abstract/Free Full Text]
  29. Bloomberg GR, Trinkaus KM, Fisher EB Jr, Musick JR, Strunk RC. Hospital readmissions for childhood asthma: a 10-year metropolitan study. Am J Respir Crit Care Med 2003;167:1068–1076.[Abstract/Free Full Text]
  30. McConnell R, Berhane K, Gilliland F, Molitor J, Thomas D, Lurmann F, Avol E, Gauderman WJ, Peters JM. Prospective study of air pollution and bronchitic symptoms in children with asthma. Am J Respir Crit Care Med 2003;168:790–797.[Abstract/Free Full Text]
  31. David GL, Romieu I, Sienra-Monge JJ, Collins WJ, Ramirez-Aguilar M, Rio-Navarro BE, Reyes-Ruiz NI, Morris RW, Marzec JM, London SJ. Nicotinamide adenine dinucleotide (phosphate) reduced:quinone oxidoreductase and glutathione s-transferase m1 polymorphisms and childhood asthma. Am J Respir Crit Care Med 2003;168:1199–1204.[Abstract/Free Full Text]
  32. Elliot JG, Carroll NG, James AL, Robinson PJ. Airway alveolar attachment points and exposure to cigarette smoke in utero. Am J Respir Crit Care Med 2003;167:45–49.[Abstract/Free Full Text]
  33. Plopper CG, Nishio SJ, Schelegle ES. Tethering tracheobronchial airways within the lungs. Am J Respir Crit Care Med 2003;167:2–3.[Free Full Text]
  34. Gilliland FD, Berhane K, Li YF, Rappaport EB, Peters JM. Effects of early onset asthma and in utero exposure to maternal smoking on childhood lung function. Am J Respir Crit Care Med 2003;167:917–924.[Abstract/Free Full Text]
  35. Singh SP, Barrett EG, Kalra R, Razani-Boroujerdi S, Langley RJ, Kurup V, Tesfaigzi Y, Sopori ML. Prenatal cigarette smoke decreases lung cAMP and increases airway hyperresponsiveness. Am J Respir Crit Care Med 2003;168:342–347.[Abstract/Free Full Text]
  36. Murphy VE, Gibson PG, Giles WB, Zakar T, Smith R, Bisits AM, Kessell CG, Clifton VL. Maternal asthma is associated with reduced female fetal growth. Am J Respir Crit Care Med 2003;168:1317–1323.[Abstract/Free Full Text]
  37. Kallapur SG, Jobe AH, Ikegami M, Bachurski CJ. Increased IP-10 and MIG expression after intra-amniotic endotoxin in preterm lamb lung. Am J Respir Crit Care Med 2003;167:779–786.[Abstract/Free Full Text]
  38. Dammann CE, Nielsen HC, Carraway KL III. Role of neuregulin-1 beta in the developing lung. Am J Respir Crit Care Med 2003;167:1711–1716.[Abstract/Free Full Text]
  39. Chang LY, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME, Crapo JD. A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2003;167:57–64.[Abstract/Free Full Text]
  40. Tanswell AK, Jankov RP. Bronchopulmonary dysplasia: one disease or two? Am J Respir Crit Care Med 2003;167:1–2.[Free Full Text]
  41. Ahmed MN, Suliman HB, Folz RJ, Nozik-Grayck E, Golson ML, Mason SN, Auten RL. Extracellular superoxide dismutase protects lung development in hyperoxia-exposed newborn mice. Am J Respir Crit Care Med 2003;167:400–405.[Abstract/Free Full Text]
  42. Jankov RP, Luo X, Campbell A, Belcastro R, Cabacungan J, Johnstone L, Frndova H, Lye SJ, Tanswell AK. Fibroblast growth factor receptor-1 and neonatal compensatory lung growth after exposure to 95% oxygen. Am J Respir Crit Care Med 2003;167:1554–1561.[Abstract/Free Full Text]
  43. Subramaniam M, Sugiyama K, Coy DH, Kong Y, Miller YE, Weller PF, Wada K, Wada E, Sunday ME. Bombesin-like peptides and mast cell responses: relevance to bronchopulmonary dysplasia? Am J Respir Crit Care Med 2003;168:601–611.[Abstract/Free Full Text]
  44. American Thoracic Society. Proceedings of the first Jack Pepys Occupational Asthma Symposium. Am J Respir Crit Care Med 2003;167:450–471.
  45. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003;167:1600–1619.[Abstract/Free Full Text]
  46. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003;167:695–701.[Abstract/Free Full Text]
  47. Fehrenbach A, Bube C, Hohlfeld JM, Stevens P, Tschernig T, Hoymann HG, Krug N, Fehrenbach H. Surfactant homeostasis is maintained in vivo during keratinocyte growth factor-induced rat lung type II cell hyperplasia. Am J Respir Crit Care Med 2003;167:1264–1270.[Abstract/Free Full Text]
  48. Augusto LA, Synguelakis M, Espinassous Q, Lepoivre M, Johansson J, Chaby R. Cellular antiendotoxin activities of lung surfactant protein C in lipid vesicles. Am J Respir Crit Care Med 2003;168:335–341.[Abstract/Free Full Text]
  49. Wu YZ, Medjane S, Chabot S, Kubrusly FS, Raw I, Chignard M, Touqui L. Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB. Am J Respir Crit Care Med 2003;168:692–699.[Abstract/Free Full Text]
  50. Marttila R, Haataja R, Guttentag S, Hallman M. Surfactant protein a and B genetic variants in respiratory distress syndrome in singletons and twins. Am J Respir Crit Care Med 2003;168:1216–1222.[Abstract/Free Full Text]
  51. Ballard PL, Merrill JD, Godinez RI, Godinez MH, Truog WE, Ballard RA. Surfactant protein profile of pulmonary surfactant in premature infants. Am J Respir Crit Care Med 2003;168:1123–1128.[Abstract/Free Full Text]
  52. Dargaville PA, Mills JF, Headley BM, Chan Y, Coleman L, Loughnan PM, Morley CJ. Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am J Respir Crit Care Med 2003;168:456–463.[Abstract/Free Full Text]
  53. Kinsella JP. Meconium aspiration syndrome: is surfactant lavage the answer? Am J Respir Crit Care Med 2003;168:413–414.[Free Full Text]
  54. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167:1562–1566.[Abstract/Free Full Text]
  55. Arkwright PD, Pravica V, Geraghty PJ, Super M, Webb AK, Schwarz M, Hutchinson IV. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 2003;167:384–389.[Abstract/Free Full Text]
  56. Accurso FJ, Sontag MK. Seeking modifier genes in cystic fibrosis. Am J Respir Crit Care Med 2003;167:289–290.[Free Full Text]
  57. Grasemann H, van's Gravesande KS, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:390–394.[Abstract/Free Full Text]
  58. Carpagnano GE, Barnes PJ, Geddes DM, Hodson ME, Kharitonov SA. Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am